Chimeric Therapeutics Limited
CHMMF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $4 | $0 | $5 | $3 |
| % Growth | – | -100% | 72.2% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $1 |
| Gross Profit | $3 | -$0 | $5 | $2 |
| % Margin | 78.7% | – | 100% | 63.7% |
| R&D Expenses | $10 | $11 | $14 | $6 |
| G&A Expenses | $7 | $9 | $12 | $9 |
| SG&A Expenses | $7 | $10 | $12 | $11 |
| Sales & Mktg Exp. | $0 | $1 | $0 | $3 |
| Other Operating Expenses | $1 | $0 | $3 | $0 |
| Operating Expenses | $18 | $21 | $29 | $17 |
| Operating Income | -$15 | -$21 | -$25 | -$15 |
| % Margin | -380.8% | – | -556.6% | -576.7% |
| Other Income/Exp. Net | $5 | -$1 | -$0 | -$1 |
| Pre-Tax Income | -$10 | -$21 | -$25 | -$16 |
| Tax Expense | $0 | -$9 | $0 | $0 |
| Net Income | -$10 | -$13 | -$26 | -$16 |
| % Margin | -262.8% | – | -566% | -607.5% |
| EPS | -0.008 | -0.018 | -0.059 | -0.044 |
| % Growth | 57.2% | 69.4% | -33.3% | – |
| EPS Diluted | -0.008 | -0.018 | -0.059 | -0.044 |
| Weighted Avg Shares Out | 1,352 | 696 | 433 | 360 |
| Weighted Avg Shares Out Dil | 1,352 | 696 | 433 | 360 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$9 | -$11 | -$24 | -$14 |
| % Margin | -228.7% | – | -533% | -520.5% |